Peptides Guide
Peptides Guide: GH Secretagogues, BPC-157, TB-500 & More (UK 2026)
Peptides represent one of the most rapidly growing areas of performance enhancement, recovery medicine, and longevity research. Unlike anabolic steroids, which directly replace or augment hormones, most performance-relevant peptides work by stimulating the body's own hormonal systems — making the pituitary release more growth hormone, accelerating tissue repair, or modulating inflammation. This guide provides a complete overview of the peptide categories most relevant to UK athletes and performance enthusiasts.
What Are Peptides?
Peptides are short chains of amino acids (typically 2–50 amino acids) that function as biological signalling molecules. The human body produces thousands of endogenous peptides — including insulin, oxytocin, and growth hormone itself. Synthetic peptides used in performance enhancement are designed to mimic or potentiate endogenous signalling pathways, typically with greater stability or specificity than their natural counterparts.
Critically: peptides are not anabolic steroids. They work through entirely different mechanisms, are structurally distinct, and — in many cases — exist in a different regulatory category in the UK (research chemicals rather than controlled substances, though this varies by compound and use context).
Categories of Performance Peptides
Growth Hormone Secretagogues (GHS)
These peptides stimulate the pituitary gland to release endogenous growth hormone (GH). They differ from exogenous HGH in a critical way: they produce pulsatile, physiological GH release — mimicking the body's natural GH pulse pattern — rather than the sustained, supraphysiological GH elevation from injecting HGH directly. This preserves the natural feedback regulation of the GH axis and is associated with lower side effect risk than exogenous HGH.
Key GH secretagogues:
- GHRH analogues (CJC-1295, Mod GRF 1-29): Mimic growth hormone-releasing hormone, stimulating GH release from the pituitary
- GHRPs (GHRP-6, GHRP-2, Ipamorelin): Ghrelin receptor agonists that stimulate GH release through a separate pathway; most effective when combined with a GHRH analogue
- Ipamorelin: A highly selective GHRP with minimal off-target effects (minimal cortisol and prolactin stimulation compared to GHRP-6/GHRP-2) — the preferred GHRP for most athletes
- MK-677 (Ibutamoren): An oral GH secretagogue (technically not a peptide but a non-peptide GHS) that stimulates GH through ghrelin receptor agonism
Tissue Repair Peptides
- BPC-157 (Body Protection Compound 157): A 15-amino acid peptide derived from a gastric protein. Extraordinary tissue repair properties in animal research: tendon, ligament, muscle, bone, and gut healing. Used by athletes for injury recovery.
- TB-500 (Thymosin Beta-4): A synthetic fragment of thymosin beta-4 that promotes angiogenesis, muscle cell differentiation, and wound healing. Particularly valued for its systemic distribution allowing it to reach injury sites throughout the body when injected subcutaneously.
- GHK-Cu (Copper Peptide): A naturally occurring copper complex with wound healing, collagen synthesis, and anti-inflammatory properties. Available in topical form.
Fat Loss and Metabolic Peptides
- AOD-9604: A fragment of the HGH molecule (residues 176–191) that retains the lipolytic (fat-burning) properties of HGH without its growth-promoting effects. No significant IGF-1 elevation.
- CJC-1295 + Ipamorelin combination: Produces GH-driven fat mobilisation while maintaining muscle mass — widely used for body recomposition.
- Semaglutide/Tirzepatide: GLP-1 receptor agonists originally developed for type 2 diabetes now widely prescribed for weight loss. While technically peptides/peptide analogues, they are licensed pharmaceutical medicines and function via a distinct mechanism from sports performance peptides. See a GP for prescription access.
Why Choose Peptides Over HGH?
| Factor | GH Secretagogue Peptides | Exogenous HGH (Somatropin) |
|---|---|---|
| GH release pattern | Pulsatile (physiological) | Sustained (supraphysiological) |
| IGF-1 elevation | Moderate | High (dose-dependent) |
| Acromegaly risk | Very low | Present at high doses long-term |
| Carpal tunnel risk | Low | Common at higher doses |
| Cost | Significantly lower | High |
| UK legal status | Research chemicals (no prescription required for possession) | Prescription-only medicine (POM) |
| Preserves natural feedback | Yes | No — suppresses natural GH |
The Best Peptide Stack for Most Athletes: CJC-1295 + Ipamorelin
The combination of a GHRH analogue (CJC-1295) and a selective GHRP (Ipamorelin) is widely considered the gold-standard peptide protocol for general performance enhancement and body recomposition. It works because the two compounds stimulate GH release via complementary pathways, producing a synergistic GH pulse significantly larger than either compound alone.
Typical protocol: CJC-1295 100–300 mcg + Ipamorelin 100–300 mcg, injected subcutaneously, 1–3 times daily (before sleep is most important; pre-training and morning are additional dosing windows). See our CJC-1295 and Ipamorelin complete guide for full protocol detail. Browse peptide products.
BPC-157: The Injury Recovery Peptide
BPC-157 has attracted substantial research attention for its tissue healing properties. In animal models it has demonstrated accelerated healing of tendons, ligaments, muscle tears, bone fractures, and gut injuries. It promotes angiogenesis (new blood vessel formation), fibroblast proliferation, and collagen synthesis at injury sites. See our BPC-157 complete guide.
TB-500: The Systemic Recovery Peptide
TB-500 (thymosin beta-4 fragment) is particularly valued for its systemic action: when injected subcutaneously at any site, it distributes throughout the body and reaches injury sites via the bloodstream. This makes it practical for injuries in areas that are difficult to inject locally. It is often stacked with BPC-157 for comprehensive injury recovery protocols. See our TB-500 complete guide.
Reconstitution and Administration
Virtually all performance peptides are supplied as lyophilised (freeze-dried) powder in vials and require reconstitution with bacteriostatic water before injection:
- Draw the appropriate volume of bacteriostatic water into an insulin syringe
- Inject it slowly down the inside of the peptide vial — do not aim directly at the powder
- Gently swirl to dissolve — do not shake (shaking can damage peptide structure)
- Refrigerate reconstituted peptides; use within 28 days
- Inject subcutaneously (abdominal fat, thigh) using an insulin syringe (27–31 gauge)
Frequently Asked Questions
Are peptides safer than steroids?
They carry different risks rather than categorically fewer risks. GH secretagogue peptides avoid the HPG axis suppression, liver toxicity, and cardiovascular lipid disruption of anabolic steroids. Their primary risks relate to GH-axis effects (mild insulin resistance at higher doses, potential long-term impact on IGF-1 if sustained for years). Tissue repair peptides like BPC-157 and TB-500 have extremely limited human clinical trial data — most evidence is from animal models. The risk of harm is generally considered lower than anabolic steroids, but the human evidence base is also substantially smaller.
Do you need PCT after peptides?
No. GH secretagogue peptides do not suppress the HPG axis (testosterone, LH, FSH remain unaffected). No PCT is required after discontinuing peptide protocols. This is a significant advantage over anabolic steroids.
Can peptides be used alongside steroids?
Yes — this is common practice. GH secretagogue peptides are frequently used alongside testosterone-based cycles to amplify recovery, fat loss, and connective tissue adaptation. BPC-157 and TB-500 are used during cycles to manage joint and connective tissue stress from heavy training on steroids. See our HGH dosage guide for context on GH-axis protocols in combination with anabolic steroids.
Medical Disclaimer: Most performance peptides are sold as research chemicals without clinical approval for human use. BPC-157, TB-500, CJC-1295, and Ipamorelin lack comprehensive human clinical trial data. This article is for informational purposes only. Use of any performance peptide should be approached with awareness of this limited evidence base.
About the Author: Dr. Sarah Mitchell holds a PhD in Endocrinology from the University of Edinburgh and is a Research Associate specialising in hormonal medicine and peptide pharmacology.
